Clinuvel Pharmaceuticals Limited CUVL
Annual
Quarterly
FY2026 · ended Jun 30, 2026 · Revenue $64.32M · Filed Oct 30, 2026
Clinuvel Pharmaceuticals Limited (CUVL) files with the SEC under industry code 8880, American Depositary Receipts. In fiscal 2026, which ended Jun 30, 2026, it reported revenue of $64.3 million and net income of $23.2 million. Free cash flow was $11.8 million. As of Jun 30, 2026 it held $174.0 million in cash and investments and $1.3 million in total debt.
Revenue
$64.32M
Net income
$23.18M
Operating cash flow
$12.91M
Free cash flow
$11.85M
EPS
$0.46
Dividend per share
None
Shares outstanding
50.43M
Net cash
$172.67M
FY 2026
Operating margin
43.4%
FY 2026
Company profile
- Industry
- American Depositary Receipts (SIC 8880)
- Listed as
- CUVL (Nasdaq), CLVLF (OTC)
- Fiscal year ends
- June 30
- Incorporated in
- Australia
- Headquarters
- Melbourne, Victoria
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1290877
- Former names
- EpiTan LTD (until Mar 20, 2006)
Other American Depositary Receipts companies
- Kongsberg Gruppen ASA/ADR KBGGY
- Sumitomo Electric Industries LTD/ADR/ SMTOY
- MTN Group LTD/ADR MTNOY
- Daiwa Securities Group Inc. DSEEY
- Yara International ASA YARIY
- Weir Group PLC/ADR WEGRY
- Pandora A/S / ADR PNDRY
- Vibra Energia S.A./ADR VBREY
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2026 Jun 30, 2026 |
|---|---|
| Revenue | $64.3M |
| Operating income | $27.9M |
| Net income | $23.2M |
| Diluted EPS | $0.46 |
| Operating cash flow | $12.9M |
| Free cash flow | $11.8M |
| Total assets | $204.0M |
| Total liabilities | $15.4M |
| Stockholders' equity | $188.6M |
| Cash and investments | $174.0M |
| Total debt | $1.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 20-F | Annual report (foreign issuer) | Oct 30, 2026 | Jun 30, 2026 |
| 6-K | Current report (foreign issuer) | Oct 30, 2026 | Oct 30, 2026 |
| 6-K | Current report (foreign issuer) | Oct 15, 2026 | Oct 15, 2026 |
| 6-K | Current report (foreign issuer) | Oct 7, 2026 | Oct 7, 2026 |
| 6-K | Current report (foreign issuer) | Oct 2, 2026 | Oct 2, 2026 |
| 6-K | Current report (foreign issuer) | Oct 1, 2026 | Oct 1, 2026 |
All 49 Clinuvel Pharmaceuticals Limited SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.